Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Company

Eli Lilly and Company

Tracked across 106 events · 2859 articles · First seen Mar 09, 2018 · Last active Sep 24, 2026

Sentiment
17
Attention
10
Events
106
Relationships
130
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
4 70
Business
Impact: Eli Lilly and Company has launched its cancer drug Tanstrive in India, expanding its market presence and offering a new treatment option for patients with RET-altered cancers. This launch is expected to positively impact the company's revenue and reputation in the Indian market.
Jun 25, 2026 · 7 articles
6 60
Business
Impact: Eli Lilly and Company obtained exclusive worldwide rights (excluding Korea) to develop, manufacture, and commercialize sonefpeglutide, expanding its pipeline in areas like short bowel syndrome and other indications, potentially leading to new revenue streams.
Jun 01, 2026 · 11 articles
4 70
Business
Impact: Eli Lilly and Company is acquiring three vaccine developers, marking its re-entry into the infectious disease space and expanding its R&D efforts. This move is expected to support its growth beyond its core diabetes and obesity portfolio.
May 26, 2026 · 7 articles
4 15
Business
Impact: Eli Lilly is the acquirer, paying $2.8B upfront for Atai Life Sciences to bolster its neuroscience pipeline and diversify beyond its weight-loss drug franchise. The deal is part of a broader acquisition spree funded by strong commercial performance.
Jul 16, 2026 · 25 articles
4 90
Tech
Impact: Manufacturer of Tirzepatide; reported strong sales growth and benefits from positive study results.
Aug 05, 2026 · 13 articles
4 60
Regulatory
Impact: Eli Lilly is the plaintiff, filing six lawsuits and escalating its campaign against unauthorized sellers of retatrutide. The company also delayed its FDA submission to Q1 2027 and allowed limited early access, reflecting both legal and regulatory actions that protect its pipeline and market position.
Aug 12, 2026 · 6 articles
4 30
Business
Impact: Acquirer; pays up to $2.875 billion to expand immunology pipeline, adding MER511 and platform. Stock down ~1.7% on announcement.
Aug 31, 2026 · 22 articles
6 90
Business
Impact: Central company; reported record revenue, raised guidance, and saw stock surge. Multiple acquisitions and pipeline progress bolster growth outlook.
Aug 23, 2026 · 6 articles
2 15
Business
Eli Lilly and Company announced on September 11, 2026 the successful completion of its acquisition of Atai Life Sciences, a clinical-stage biopharmaceutical company developing rapid-acting neuroplastogens for mental health conditions. AtaiBeckley's lead investigational program, BPL-003,…
Impact: Eli Lilly is the acquirer, adding AtaiBeckley's rapid-acting neuroplastogen pipeline, including BPL-003 for treatment-resistant depression, to its neuroscience portfolio. The deal is a modest strategic positive, though undisclosed terms and early-stage assets limit near-term financial impact.
Sep 11, 2026 · 6 articles
4 25
Business
Eli Lilly and Company shares fell roughly 7-8% over the month preceding mid-September 2026, sliding from about $1,255 to around $1,115-1,165, even as the broader S&P 500 advanced. The decline followed realized U.S. price declines…
Impact: Central subject of the event: shares fell about 7-8% over the month on pricing and IPR&D charges despite strong Q2 beats and raised 2026 guidance. Citi's Street-high $1,600 target frames the selloff as overdone, leaving the stock as the widest analyst-implied upside in its pharma peer group.
Sep 14, 2026 · 6 articles
4 25
Business
Eli Lilly and Company formally broke ground on a $6.5 billion pharmaceutical manufacturing campus in northeast United States — Houston, United States — Texas, at Generation Park near Beltway 8. The 236-acre site is part…
Impact: Eli Lilly is the primary actor, investing $6.5 billion to expand manufacturing capacity for Foundayo and other medicines, strengthening its supply chain and market position.
Sep 21, 2026 · 7 articles
6 70
Business
Impact: Main rival; maintains lead with Tirzepatide and Tirzepatide, but faces lawsuit and competition from oral Semaglutide.
Aug 03, 2026 · 6 articles
4 25
Regulatory
Eli Lilly and Company announced that the U.S. United States — Food and Drug Administration granted full approval to Inluriyo (imlunestrant), an oral estrogen receptor antagonist, in combination with Abemaciclib (abemaciclib), a CDK4/6 inhibitor, for…
Impact: Eli Lilly receives FDA full approval for Inluriyo plus Abemaciclib, expanding its oncology franchise and adding a new revenue stream. The approval strengthens its competitive position in breast cancer treatment.
Sep 18, 2026 · 6 articles
6 -80
Tech
Impact: Eli Lilly and Company produces donanemab (Kisunla), one of the anti-amyloid drugs whose effectiveness was questioned by the Cochrane review, potentially impacting its sales and stock price.
Apr 16, 2026 · 6 articles
8 70
Business
Impact: Eli Lilly and Company is a leading pharmaceutical company with strong balance sheets, enabling it to be a major acquirer in the current M&A wave. It is also facing patent expirations on some of its blockbuster drugs.
May 01, 2026 · 6 articles
3 60
Business
Impact: Eli Lilly and Company has partnered with DKSH to expand the distribution and promotion of its pharmaceutical products in China — Hong Kong and China — Macau, ensuring continued patient access to its medicines.
Jul 06, 2026 · 6 articles
8 70
Tech
Impact: As the parent company of Verve PCSK9-inhibitor gene therapy>>>, Eli Lilly and Company>>> is a key developer of VERVE-102, a gene-editing therapy that has shown promising results in lowering cholesterol. This breakthrough could significantly impact its future market position in cardiovascular medicine.
May 26, 2026 · 12 articles
4 50
Business
Impact: Eli Lilly and Company expanded its exclusive global rights to Camurus' Fluid Crystal technology, allowing it to develop and commercialize long-acting cardiometabolic drugs for an additional compound class, which could lead to new revenue streams.
Jun 01, 2026 · 10 articles
4 70
Business
Impact: Lilly leads GLP-1 sales in China and runs prominent awareness campaigns, though it paused its India campaign. Its Mounjaro is gaining patient demand.
Aug 24, 2026 · 6 articles
4 75
Regulatory
Impact: Eli Lilly partnered with Roche in developing the test and will benefit from royalties or shared revenue, strengthening its presence in Alzheimer's diagnostics.
Aug 24, 2026 · 7 articles
4 -30
Regulatory
Hundreds of patients in the United States have filed personal injury lawsuits against Novo Nordisk and Eli Lilly and Company, alleging that widely used GLP-1 medications including Ozempic, Wegovy, Mounjaro, Zepbound and Trulicity caused a…
Impact: Co-defendant in the NAION litigation involving Mounjaro, Zepbound and Trulicity. It says patient safety is its top priority and that it monitors safety reports, but the lawsuits create legal and reputational exposure for its GLP-1 portfolio.
Sep 21, 2026 · 20 articles
8 70
Tech
Impact: Eli Lilly and Company>>> produces GLP-1 drugs like Zepbound, Mounjaro, and Trulicity, which are showing potential benefits in cancer prevention and treatment.
Jun 02, 2026 · 45 articles
4 70
Tech
A study led by NYU Langone Health, published in the journal Pediatrics on September 4, 2026, found that prescriptions for GLP-1 weight-loss drugs (Saxenda, Wegovy, Zepbound) among US children aged 8-11 with obesity increased 310-fold…
Impact: Manufacturer of Zepbound; increased pediatric use may boost sales.
Sep 04, 2026 · 7 articles
2 15
Business
Altor BioScience Corporation announced an agreement with Lilly TuneLab, a collaborative AI/ML drug discovery platform created by Eli Lilly and Company. Under the agreement, Twist will provide antibody characterization data services for TuneLab, including for…
Impact: Eli Lilly expands its TuneLab platform ecosystem through the Twist agreement, adding high-quality wet lab antibody data to support its AI models. The deal reinforces Lilly's leadership in AI-enabled drug discovery with limited direct financial impact.
Sep 16, 2026 · 6 articles
4 -60
Regulatory
Impact: Eli Lilly and Company is a pharmaceutical company also facing lawsuits for its GLP-1 medications, Tirzepatide and Tirzepatide, which are alleged to have caused NAION. The company is accused of failing to warn consumers about these risks.
May 22, 2026 · 7 articles
6 -20
Business
Impact: Eli Lilly and Company faces increased competition with Novo Nordisk's Wegovy pill launch, potentially impacting its market dominance in weight-loss drugs. Its shares fell following the announcement.
Jan 05, 2026 · 7 articles
6 -30
Tech
Impact: Eli Lilly and Company produces Tirzepatide and Tirzepatide, which are GLP-1 agonist drugs. The study's findings on rapid weight regain after stopping medication could affect the perceived long-term efficacy and market demand for their products.
Jan 08, 2026 · 6 articles
4 20
Tech
Impact: Eli Lilly and Company collaborated on a new study that found a 71% higher risk of cardiovascular events or death in people with obstructive sleep apnea, especially those with obesity. This research could influence the development of new treatments and diagnostics, potentially benefiting Eli Lilly and Company's market position in related therapeutic areas.
Apr 03, 2026 · 6 articles
6 60
Domestic
Impact: Eli Lilly and Company's drug, Tirzepatide, is also included in France's reimbursement plan, which will expand its market reach within the European Union.
May 28, 2026 · 6 articles
2 60
Business
Impact: Eli Lilly completed its acquisition of KC Pharmaceuticals, strengthening its sleep disorder portfolio. Nxera retains rights to future milestone and royalty payments from the orexin programs, benefiting Lilly's pipeline.
Aug 07, 2026 · 6 articles
+ 76 more events View on Dashboard
35 China included Mounjaro in reimbursement list Eli Lilly and CompanyEli Lilly GLP-1 Selloff...
20 Eli Lilly and Company acquired radiopharmaceutical companiesTelix acquires ITM Isotope...
10 Eli Lilly and Company hired researcher Ziyuan WangMenopause Hormone Therapy...
Novo Nordisk ↔ Eli Lilly and Company
Novo Nordisk ↔ Eli Lilly and Company
Nike, Inc. ↔ Eli Lilly and Company
Nike, Inc. ↔ Eli Lilly and Company
Bristol Myers Squibb ↔ Eli Lilly and Company
Bristol Myers Squibb ↔ Eli Lilly and Company
Biogen ↔ Eli Lilly and Company
Biogen ↔ Eli Lilly and Company
MSCI World ↔ Eli Lilly and Company
MSCI World ↔ Eli Lilly and Company
Pfizer ↔ Eli Lilly and Company
Pfizer ↔ Eli Lilly and Company
Sanofi ↔ Eli Lilly and Company
Sanofi ↔ Eli Lilly and Company
S&P Dow Jones Indices ↔ Eli Lilly and Company
S&P Dow Jones Indices ↔ Eli Lilly and Company
Sun Pharma ↔ Eli Lilly and Company
Sun Pharma ↔ Eli Lilly and Company
Marvell Technology ↔ Eli Lilly and Company
Marvell Technology ↔ Eli Lilly and Company
GSK plc ↔ Eli Lilly and Company
GSK plc ↔ Eli Lilly and Company
Snowflake Inc. ↔ Eli Lilly and Company
Snowflake Inc. ↔ Eli Lilly and Company
Hang Seng Index ↔ Eli Lilly and Company
Hang Seng Index ↔ Eli Lilly and Company
+ 100 more relationships View on Dashboard
ERGEN INTELLIGENCE
Track Eli Lilly and Company live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.